



Advicenne 2025 Universal Registration Document made available

Paris (France), April 24, 2026 – 6.00 pm CET – Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces today that its 2025 Universal Registration Document has been filed with the French Autorité des Marchés Financiers (AMF).

The Universal Registration Document includes the annual report, the management report, the Board of Directors' report on corporate governance and the Statutory Auditors' reports. It also contains a description of the share buyback program.

The Universal Registration Document is available on Advicenne's website (www.advicenne.com) in the Investors/Financial Information section and on the AMF website (www.amf-france.org).

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnaya[®] (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. **For additional information see:** <https://advicenne.com/>.

CONTACTS

Advicenne

Didier Laurens, CEO

+33 (0)1 87 44 40 17

Email: investors@advicenne.com

Maarc - Relations presse

Bruno Arabian

+33 (0)6 87 88 47 26

Email: bruno.arabian@maarc.fr